SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced new research published in the peer-reviewed Journal of Investigative Dermatology describing the positive effects of ART26.12 in both in vitro and in vivo psoriasis models, showing results comparable to immunom ...